No 13F manager has reported this stock in the last 8 quarters.
None.
None.
No insider has filed a notice of proposed sale (Form 144) for Interpace Biosciences Inc in the last 12 months.
No 13F manager reports holding IDXG.
| Fund | Position value | Shares | % of company | % of the fund | As of |
|---|---|---|---|---|---|
|
EM
USAA Mutual Funds Trust
|
$2.1K | 438 | 0.00% | 0.00% | March 31, 2022 |
|
TS
John Hancock Variable Insurance Trust
|
$944 | 276 | 0.00% | 0.00% | June 30, 2022 |
| Holder | Shares | % of company | Change vs last qtr | 8 quarters | Held since | % of their book |
|---|---|---|---|---|---|---|
|
BT
Burnell Thomas W.
Insider
|
1.5M | 5.53% | — | — |
— | — |
|
Insider holdings come from Form 3/4/5 filings, which are not quarterly.
Share of the company5.530%
|
||||||
|
MC
McCarthy Christopher
Insider
|
323.8K | 1.17% | — | — |
— | — |
|
Insider holdings come from Form 3/4/5 filings, which are not quarterly.
Share of the company1.170%
|
||||||
Loading...